SUSTAINED ALL ROUND LEADERSHIP

Continued Outstanding Clinical Performance

Enhanced Patient Experience

FY12 Consolidated Revenues up 20.8% at Rs.31, 475 million Consolidated EBITDA up 22.5% at Rs. 5,131 million Consolidated PAT up 19.3% at Rs. 2,194 million Board recommends a dividend of Rs. 4 per share

Chennai, May 29, 2012: Apollo Hospitals Enterprise Ltd (AHEL), (BSE: 508869, NSE: INE437A01024), the Healthcare Pioneer and leading provider of quality clinical care reported its consolidated financial results according to Indian GAAP for the quarter and financial year ended March 31, 2012. The results reinforce Apollo’s leadership as the most valuable and trusted healthcare provider.

The company crossed the Rs.30 Billion milestone posting consolidated annual revenues of Rs. 31.5 Billion with a growth of 20.8% Y‐on‐Y. Consolidated EBITDA was up 22.5% at Rs.5, 131 Million with PAT growing at 19.3% at Rs.2, 194 Million. Board recommends Dividend of Rs 4 per Share

Commenting on the 2011‐12 performance, Dr. Prathap C Reddy, Chairman said, “Apollo Hospitals continues to demonstrate strong momentum and sustained leadership through the fourth quarter to close out a year of strong growth and profitability.” He added, “With our mission to give our customers the latest in treatment technologies, we have delivered clinical excellence on par with the world’s best benchmarks. The value of care is further enhanced by our acclaimed patient Care emphasis that has helped us to put in place the world’s busiest transplantation program and undertake effective initiatives such as Robotic Surgery, a minimally invasive surgery. The re‐ accreditation of our facilities at Chennai, Delhi, Bangalore and Dhaka by JCI and the NABH accreditation awarded to our hospitals in Ahmedabad, Noida and Secunderabad further underscore our rigor on standards. The team has once again delivered a robust growth, while improving profitability, which is truly a reflection of our business model.”

The year ahead per Dr. Prathap C Reddy is one of “further impetus to our key pillars of Patient Care Excellence, Clinical Excellence, Value Excellence, and thought through expansions to bring the best of technical and clinical advances for the benefit of customers. We have also initiated significant transformation initiatives that would further set us of up to achieve balanced growth across all our Centers of Excellence, Geographies and Formats. ”Our emphasis on using Information Technology to transform Health Care is yielding results in process efficiency and enhanced connectivity with Doctors & patients. Financial Highlights

● Audited Standalone FY12 Performance (in comparison to FY11) ○ Revenues grew 20.1% to Rs. 28,001 million compared to Rs. 23,320 million in FY11. ○ EBITDA grew 23.0% to Rs. 4,644 million as against Rs. 3,775 million in FY11. The EBITDA margin improved by 40 basis points to 16.6%. ○ PAT was Rs. 2,310 million vs. Rs. 1,817 million in FY11, growth of 27.1%. ○ Diluted EPS of Rs. 16.86 per share in FY12 ○ The Boards of Directors has recommended a dividend of Rs. 4 per share.

● Audited Consolidated FY12 Performance ○ Revenues grew 20.8% to Rs.31,475 million compared to Rs. 26,054 million in FY11. ○ EBITDA grew 22.5% to Rs. 5,131 million as against Rs. 4,190 million in FY11. The EBITDA margin improved by 22 basis points to 16.3%. ○ PAT was Rs. 2,194 million vs. Rs. 1,839 million in FY11, a growth of 19.3%. ○ Diluted EPS of Rs. 16.01 per share in FY12

● Audited Standalone Q4FY12 Performance (in comparison to Q4FY11) ○ Revenues grew 19.8% to Rs.7,446 million compared to Rs. 6,214 million in Q4FY11. ○ EBITDA grew 25.8% to Rs.1200 million as against Rs. 954 million in Q4FY11. ○ PAT was Rs. 593 million vs. Rs. 471 million in Q4FY11, growth of 26.0%. ○ Diluted EPS of Rs. 4.27 per share in Q4FY12

● Audited Consolidated Q4FY12 Performance ○ Revenues grew 20.4% to Rs.8,572 million compared to Rs. 7,121 million in Q4FY11. ○ EBITDA grew 25.9% to Rs. 1,309 million as against Rs. 1,039 million in Q4FY11. ○ PAT was Rs. 515 million vs. Rs. 466 million in Q4FY11, growth of 10.4%. ○ Diluted EPS of Rs. 3.70 per share in Q4FY12

Clinical Highlights

Apollo Transplant Institutes: (ATI)

We completed 929 Solid organ transplants in a single calendar Year to be the first to reach this milestone and become the busiest program of its kind in the world.

New transplant facilities started in Bhubaneshwar and Ludhiana while consolidating its programs in Bangalore and Hyderabad.

Apollo Institute of Robotic Surgery:

This was launched in Chennai in November 2011 and has successfully completed 55 complicated surgeries with robotic assistance.

Expanding this reach in Cardiac, Head and Neck Surgeries.

Radiation Therapy:

Plans to introduce TrueBeam Stx , during the first quarter of FY13 in Bangalore . Considered as one of the world’s most advanced radiation therapy machine, the TrueBeam Stx is an advanced radiation therapy machine engineered to perform the most sophisticated radiation therapy and radio‐surgery procedures with pinpoint accuracy and ultra‐fine precision. It will enable faster, accurate tumor targeting in the treatment of challenging cancers throughout the body, including those in the brain, pancreas and liver. Cardiac Excellence:

The Cardiac CoE has thus far completed over 120,000 surgeries, a global milestone.

Clinical Benchmarks:

Further enhancement of focus on our respected Global Clinical Excellence Benchmark program (ACE @25) that measures clinical outcome across 25 additional outcomes aligned to our Centers of Excellence. This augmented program is being run across our centers.

Attached: Details to the announcement

For further information, please contact:

R Krishnakumar Mayank Vaswani Apollo Hospitals Enterprise Ltd. Citigate Dewe Rogerson [email protected] mayank@cdr‐india.com +91 44 2829 7840 +91 22 6645 1230

About Apollo Hospitals Enterprise Ltd. (AHEL)

It was in 1983, that Dr. Prathap Reddy made a pioneering endeavour by launching India’s first corporate hospital ‐ Apollo Hospital in Chennai. Now, as Asia largest and most trusted healthcare group, its presence includes over 8,200 beds across 50 Hospitals, 1,364 Pharmacies, 100 primary care and diagnostic Clinics, 100 Telemedicine units across 9 countries, medical business process outsourcing services, Health Insurance services, Global Projects Consultancy, 15 colleges of Nursing and Hospital Management and a Research Foundation with a focus on global Clinical Trials, epidemiological studies, stem cell and genetic research.

Disclaimer

Some of the statements in this document that are not historical facts are forward looking statements. These forward‐looking statements include our financial and growth projections as well as statements concerning our plans, strategies, intentions and beliefs concerning our business and the markets in which we operate.

These statements are based on information currently available to us, and we assume no obligation to update these statements as circumstances change. There are risks and uncertainties that could cause actual events to differ materially from these forward‐looking statements. These risks include, but are not limited to, the level of market demand for our services, the highly‐competitive market for the types of services that we offer, market conditions that could cause our customers to reduce their spending for our services, our ability to create, acquire and build new businesses and to grow our existing businesses, our ability to attract and retain qualified personnel, currency fluctuations and market conditions in India and elsewhere around the world, and other risks not specifically mentioned herein but those that are common to industry.

Further, this document may make references to reports and publications available in the public domain. Apollo Hospitals Enterprise Ltd. makes no representation as to their accuracy or that the company subscribes to those views / findings.

The Company on a quarterly basis adopts and publishes Standalone financial results as per the stock exchange listing agreement requirements. The consolidated financial results provided for the Quarter are unaudited and for information purposes only.

Details to the announcement

Key Achievements – 4 Pillars

At Apollo, corporate success is anchored by 4 key pillars Clinical Excellence, Technological Excellence, Patient Care Excellence and Value Excellence. Apollo Hospitals’ believes in delivery of best patient care, employing best‐in‐class procedures and technologies with an eye on sustainable growth performance.

● Clinical Excellence: Apollo strives to maintain consistently higher rates of case success rates.

● Technological Excellence: Apollo relies on world–class, state‐of–the–art equipment, devices and procedures to consistently deliver superior clinical outcomes.

● Patient Care Excellence: Apollo is driven by patient well‐being.

● Value Excellence: Apollo balances performance goals with top‐notch healthcare service delivery which is affordable to the masses.

Operating Highlights

● The ‘Join Hands Patient Safety Campaign’ was launched by Dr Prathap C Reddy, Ms Kiran Mazumdar Shaw (Chairperson & MD ‐ Biocon) and Sir Muer Gray (Chief Knowledge Officer ‐ NHS, UK). The campaign is one that calls organizations to come on a single platform, work together and share best practices with each other. It covers 1,88,007 Hospitals working towards one common mission ‐ Patient Safety.

● The First Edition of the International Congress on Patient Safety, Best Practices for Asia was held in Hyderabad during 21 – 22 April, 2011.

● The Department of Neurosurgery, Institute of Neurosciences, Apollo Hospitals at Bhubaneswar carried out two level cervical disc replacements by prosthetic Cervical disc for the first time in the state of Odisha and eastern part of India. The patient, aged 54 years, had an excellent Neurological recovery and was discharged in 3 days.

● During FY12, Apollo Hospitals at Dhaka, Bangalore, Delhi and Chennai were re‐accredited by the JCI while Apollo Hospitals at Ahmedabad, Noida and Secunderabad received NABH Certification.

● Apollo Hospitals ,Kolkata successfully treated a patient suffering from a liver tumour with a new radiotherapy technique called Stereotactic Body Radiation Therapy (SBRT). With this technique high dose radiation was delivered precisely to the target in three fractions (one fraction on alternate days) and the radiation treatment was completed within five days.

Segment‐wise Performance Update

Hospitals

Revenues of the hospital division of Apollo Hospitals Enterprise Limited (Standalone) (consisting of hospital services, hospital‐based pharmacies and consulting) increased by 16.1% to Rs. 19,402 million in FY12 compared to Rs. 16,712 million in FY11.

 Chennai cluster displayed a healthy revenue growth in Q4 FY12.

 Hyderabad cluster continues to display strong growth. Average occupancy at 577 beds (62% utilization on 930 beds) as compared to 526 beds (65% utilization on 809 beds) in FY12. Strong volume growth on focus COE’s like Cardiology (36%), Neurosciences (23%), Gastro (27%), Transplants (64%) and Oncology (30%).

 Bhubaneswar occupancy at 144 beds (65% utilization on an increased capacity of 220 beds) as compared to 78 beds in FY12, due to increased patient footfalls and admissions. Q4FY12 EBITDA margins at 16% from 5% in the same period last year.

Standalone Pharmacies

Apollo Pharmacies reported sustained growth in revenues at Rs. 2,377 million in Q4FY12, growing 30.5% from Rs. 1,821 million in Q4FY11. The SAP business also demonstrated continued operational improvement with expansion in EBITDA of 115 bps from Rs. 24 million in Q4FY11 to Rs. 59 million in Q4FY12. The business reported improved profitability with an EBIT of Rs. 36 million in Q4FY12 compared to an EBIT of Rs. 6 million in Q4FY11.

The company continued to consolidate its pan‐India presence as it added 74 stores on a net basis in Q4FY12, taking its network to 1,364 operational stores by March 31, 2012. During Q4, it added 81 stores and closed 7 underperforming stores.

The batch of mature stores (pre March 2007) continues to perform strongly with like‐for‐like growth in revenues / store at 13% in Q4FY12. The segment of mature stores reported further improvements in profitability with an EBITDA margin of 5.8% in Q4FY12, an increase of 36 basis points over Q4FY11.

Subsidaries and JVs

Apollo Munich Health Insurance Company Limited

During FY12, the company achieved a Gross Written Premium of Rs. 4,759 million against a GWP of Rs. 2,835 million in FY11. Similarly, the earned premium demonstrated traction expanding 102% to Rs. 3,008 million in FY12 compared to Rs. 1,487 million in FY11. Driven by improved pricing and prudent underwriting, the incurred claim ratio improved to 58% in FY12 from 62% in FY11.

Improved operating metrics were apparent in the reduced loss at the EBITDA level of Rs. ‐382 million in FY12 compared to Rs. ‐705 million in FY11. The combined ratio improved from 128% in FY11 to 109% in FY12. As of Mar 31, 2012 the company has 50 offices across India and Rs. 4,192 million of AUMs.

Apollo Health Street

AHS reported revenues of Rs. 4,909 million in FY12, an increase of 9.7% compared to revenues of Rs. 4,476 million in FY11. Revenue growth was driven by increased business volumes and momentum in new business driven by a vastly strengthened sales team.

EBITDA was higher by 61.6% at Rs. 842 million in FY12 and the EBITDA margin improved by 554 basis points to 17.2%. PAT was Rs 1 million. There was also a one off litigation cost of approximately Rs. 101 million during the year.

Accreditations & Awards

● The Federation of Indian Chambers of Commerce and Industry (FICCI) awarded Dr. Prathap Reddy the Lifetime Achievement Award 2011

● At the Asian Hospital Management Awards, 2011 Apollo Hospitals, Chennai was the winner in the Operational Customer Service Project Category; Apollo Gleneagles Hospitals, Kolkata was runner‐up in the Cost Reduction Project Category and Apollo Hospitals, Hyderabad was runner‐up in the Clinical Service Improvement Project Category.

● The Apollo Clinical Excellence Forum (ACEF) was adjudged among the top 3 in the Public Choice category under “Innovative Initiatives in Healthcare” by the public in the eHealth World Awards 2011.

● The Critical Care Units of Apollo Main Hospital, Chennai and Apollo Speciality Hospital, Madurai were ranked as ‘Best of Best’ for applying evidence based nutrition practices for managing critically ill patients.

● Apollo Hospitals, Chennai was judged at the 6th place and Apollo Speciality Hospital, Madurai at the 7th place for Best Critical Care Nutrition.

‐ENDS‐

3